Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEDROXYPROGESTERONE ACETATE

All products: not a benefit

Other products in the same Health Canada class (G03D, G03DA) — coverage varies; not interchangeable

  • Progesterone (Prometrium): not a benefit
  • Dienogest (Visanne): limited Use 432

Provera · DIN 00030945 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.Discontinued 2012-02-13 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Provera · DIN 00030945 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2012-02-13 · brand PROVERA 100MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Provera: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=675 · Verify on the e-Formulary ↗ (DIN 00030945)

Source record
DIN 00030945: Provera Raw flags: notABenefit=Y, sec3=Y Item: 683200037; group id 801; item number 1962; lccId None; manufacturer id PFI Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=675
Interchangeable products
AA-Medroxy · DIN 02267640 · $1.2057
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030945
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for: • Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and significantly reduce the risk of hyperplasia and carcinoma; • Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the absence of organic pathology; • Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial carcinoma; • Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women. For indications not including breast cancer, AA-MEDROXY should be prescribed only to women with intact uteri. 1.1. Pediatrics Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): see 7 Warnings and precautions, 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00085517.PDF PM date: 2026-07-24 Source product: AA-MEDROXY; DIN 02244726; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Provera: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026